Office Action Predictor
Application No. 18/532,319

NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME

Non-Final OA §101§DP
Filed
Dec 07, 2023
Examiner
STOCKTON, LAURA LYNNE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sanofi
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
99%
With Interview

Examiner Intelligence

75%
Career Allow Rate
1007 granted / 1340 resolved
Without
With
+33.9%
Interview Lift
avg trend
2y 6m
Avg Prosecution
28 pending
1368
Total Applications
career history

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
21.1%
-18.9% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
34.6%
-5.4% vs TC avg
Black line = Tech Center average estimate • Based on career data

Office Action

§101 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1, 2, 11, 12, 22, 28, 30-32, 35, 36, 44, 48 and 50-58 are pending in the instant application. Election/Restrictions Applicant’s election without traverse of Group I, PNG media_image1.png 242 584 media_image1.png Greyscale , and the species of Compound No. 15, disclosed in Table A on page 260 (reproduced below), PNG media_image2.png 170 970 media_image2.png Greyscale PNG media_image3.png 204 960 media_image3.png Greyscale in the reply filed on June 30, 2025 is acknowledged. Upon reconsideration, the Restriction between Group I and Groups V-IX (claims 52-58) has been withdrawn. The inventions of Groups V-IX (claims 52-58) have been rejoined with Group I. The requirement is still deemed proper for the other groups and is therefore made FINAL. Claims 35, 36, 44, 48, 50 and 51 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on June 30, 2025. It is suggested that in order to advance prosecution, the non-elected subject matter in which rejoinder is not applicable be canceled if Applicant files a response to this Office Action. Power of Attorney Of note, there is not an attorney of record on file due to a lack of an official power of attorney of record. While a customer number has been provided on the Application Data Sheet (ADS) submitted December 7, 2023, this is not the equivalent of a power of attorney or an authorization to act in a representative capacity. In order to expedite prosecution in the instant application, it is suggested that a power of attorney be filed as per MPEP §402 or MPEP §1807, or an Authorization to Act in a Representative Capacity be filed as per MPEP §403 in order for the Office to freely and openly discuss the merits of the case with the applicant's representative(s). Please refer to the MPEP or http://www.uspto.gov/patents/law/poafaqs.jsp#a if you have questions regarding the proper filing of a power of attorney. " Priority Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed in parent Application No. 16/978,603, filed on September 4, 2020. This application repeats a substantial portion of prior Application No. 16/978,603, filed November 15, 2018, and adds disclosure not presented in the prior application. Because this application names the inventor or at least one joint inventor named in the prior application, it may constitute a continuation-in-part of the prior application. Should applicant desire to claim the benefit of the filing date of the prior application, attention is directed to 35 U.S.C. 120, 37 CFR 1.78, and MPEP § 211 et seq. The presentation of a benefit claim may result in an additional fee under 37 CFR 1.17(w)(1) or (2) being required, if the earliest filing date for which benefit is claimed under 35 U.S.C. 120, 121, 365(c), or 386(c) and 1.78(d) in the application is more than six years before the actual filing date of the application. Applicant has added an “incorporation by reference” statement in the instant application, which statement was deleted during the prosecution of parent Application No. 16/978,603 because the “incorporation by reference” statement was deemed new matter. See pages 4-11 of the Office Action dated February 9, 2023 in Application No. 16/978,603. Information Disclosure Statement The Examiner has considered the Information Disclosure Statement filed on March 22, 2024. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Objections Claims 1, 11 and 53 are objected to because of the following informalities: in claim 1, under the definition of X1 and X2, an “or” should be added before “a (C1-C6)alkyl group”; in claim 11, under the definition of X1 and X2, an “or” should be added before “a (C1-C6)alkyl group”; and in claim 53, after the definition of the R5 variable, the period after “alkyl group” should be changed to a semi-colon (line 2 of page 10). Appropriate correction is required. Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 1, 11, 31, 32, 52, 55 and 56 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 4 and 13-17, respectively, of prior U.S. Patent No. 11,897,911. This is a statutory double patenting rejection. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 11, 12, 22, 28, 30-32 and 52-58 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 11,897,911. Although some of the claims at issue are not identical, they are not patentably distinct from each other because the inventions under examination in the instant application were elected and examined in Parent Application No. 16/978,603 and patented in U.S. Patent No. 11,897,911. Therefore, the claims in U.S. Patent No. 11,897,911 anticipate and/or render obvious the instant claimed invention. Claims 1, 11, 12, 22, 28, 31 and 32 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 6 and 11 of copending Application No. 18/248,988 (reference application), US 2024/0092819. Although the claims at issue are not identical, they are not patentably distinct from each other because there is an overlap of subject matter claimed in the copending application with the subject matter instantly claimed. See especially claim 1 in copending Application No. 18/248,988. Further, the specification of copending Application No. 18/248,988 discloses compounds embraced by its claims, such as its claim 1. See, for instance, Entry 2 on page 39 of the specification in copending Application No. 18/248,988, which Entry 2 would anticipate the instant claimed invention. The instant application and copending Application No. 18/248,988 share at least one common inventor. The instant application is not related to copending Application No. 18/248,988 and thus, no 35 USC 121 shield exists here. See MPEP 804.01. Therefore, the claims in copending Application No. 18/248,988 render obvious the instant claimed invention. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. The elected species of Compound No. 15, disclosed in Table A on page 260, is not allowable. See the double patenting rejections above over the claims in Parent U.S. Patent No. 11,897,911. Reminder to Applicant As a reminder, Applicant should specifically point out the support in the original disclosure {i.e., page number(s) and line number(s)} for any new claims or amended claims and for any amendments made to the disclosure. Making generic statements such as “all amendments are fully supported in the originally filed disclosure or the originally filed claims” without specifying page numbers and originally filed claim numbers are insufficient. See MPEP §714.02 and MPEP §2163.06(I). Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Laura L. Stockton (571) 272-0710. The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph K. McKane can be reached on 571/272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620 Technology Center 1600 August 28, 2025 Book XXVII, page 78
Read full office action

Prosecution Timeline

Dec 07, 2023
Application Filed
Aug 28, 2025
Non-Final Rejection — §101, §DP
Apr 03, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12590209
PIGMENTED AND FLUORESCENT COMPOUNDS DERIVED FROM THE ADDITION OF A PRIMARY OR SECONDARY AMINE TO AN ALDEHYDE
2y 5m to grant Granted Mar 31, 2026
Patent 12590060
SCALABLE SYNTHETIC ROUTE FOR PSILOCIN AND PSILOCYBIN
2y 5m to grant Granted Mar 31, 2026
Patent 12581853
ORGANIC COMPOUND AND SENSOR AND SENSOR EMBEDDED DISPLAY PANEL AND ELECTRONIC DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12577234
ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
2y 5m to grant Granted Mar 17, 2026
Patent 12566173
HEMOLYTIC REAGENT, REAGENT KIT, AND METHOD FOR CLASSIFYING WHITE BLOOD CELLS
2y 5m to grant Granted Mar 03, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+33.9%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1340 resolved cases by this examiner